Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis

(2021) Nico Hinz et al.   Cells

The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy

(2020) Ross Mudgway et al.   ANNALS OF SURGICAL ONCOLOGY

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

(2020) Sandra M Swain et al.   LANCET ONCOLOGY

Breast cancer is a systemic disease optimally treated by a multidisciplinary team

(2020) Nadia Harbeck   Nature Reviews Disease Primers

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

(2020) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of brain metastases according to molecular subtypes

(2020) Riccardo Soffietti et al.   Nature Reviews Neurology

Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study

(2020) Deyue Liu et al.   Frontiers in Oncology

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01

(2018) Atilla Soran et al.   ANNALS OF SURGICAL ONCOLOGY

Bone metastasis pattern in initial metastatic breast cancer: a population-based study

(2018) Zhenchong Xiong et al.   Cancer Management and Research

Metastatic bone disease: Pathogenesis and therapeutic options

(2018) Stella D'Oronzo et al.   Journal of Bone Oncology

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

(2017) Véronique Diéras et al.   LANCET ONCOLOGY

Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study

(2017) Qi Wu et al.   Oncotarget

Dietary factors and polymorphisms in vitamin D metabolism genes: the risk and prognosis of colorectal cancer in northeast China

(2017) Chen Gong et al.   Scientific Reports

Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer

(2016) Joachim Diessner et al.   BMC CANCER

Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients

(2016) Brigitte Rack et al.   ONCOLOGY

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial

(2015) Rajendra Badwe et al.   LANCET ONCOLOGY

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse

(2013) A. D. Hartkopf et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

(2013) Dorien J. A. Lobbezoo et al.   BREAST CANCER RESEARCH AND TREATMENT

Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden

(2013) Omar M. Rashid et al.   SURGERY

Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients

(2011) Brigitte Rack et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Metastatic Behavior of Breast Cancer Subtypes

(2010) Hagen Kennecke et al.   JOURNAL OF CLINICAL ONCOLOGY